Savara (NASDAQ:SVRA) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Posted by Brenda Bartman on Nov 11th, 2026

Savara (NASDAQ:SVRA – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01, reports.

Savara Trading Up 4.0%

NASDAQ SVRA traded up $0.20 during trading on Wednesday, reaching $5.12. 2,905,215 shares of the stock traded hands, compared to its average volume of 1,763,256. Savara has a fifty-two week low of $4.03 and a fifty-two week high of $7.01. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -8.82 and a beta of 0.32. The stock’s 50-day moving average price is $4.97 and its 200 day moving average price is $5.35.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SVRA shares. JPMorgan Chase & Co. initiated coverage on Savara in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. Royal Bank Of Canada set a $10.00 price objective on Savara in a report on Wednesday, October 7th. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.25.

Get Our Latest Research Report on Savara

Savara Company Profile

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.